Novartis (NVS) Set to Announce Quarterly Earnings on Tuesday

Novartis (NYSE:NVS) will be releasing its earnings data before the market opens on Tuesday, April 23rd. Analysts expect Novartis to post earnings of $1.73 per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, January 30th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $11.42 billion for the quarter, compared to the consensus estimate of $11.69 billion. Novartis had a net margin of 29.83% and a return on equity of 29.90%. During the same period last year, the company posted $1.51 earnings per share. On average, analysts expect Novartis to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Novartis Stock Performance

Shares of NYSE NVS traded up $1.10 during midday trading on Monday, hitting $95.46. 302,269 shares of the company’s stock were exchanged, compared to its average volume of 1,480,934. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.15 and a quick ratio of 0.93. The stock’s 50 day moving average price is $98.09 and its 200-day moving average price is $99.00. The firm has a market cap of $195.12 billion, a P/E ratio of 13.20, a PEG ratio of 1.47 and a beta of 0.54. Novartis has a twelve month low of $92.19 and a twelve month high of $108.78.

Novartis Increases Dividend

The firm also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Stockholders of record on Friday, March 8th were given a dividend of $3.7772 per share. The ex-dividend date was Thursday, March 7th. This is an increase from Novartis’s previous annual dividend of $3.47. This represents a dividend yield of 3.1%. Novartis’s payout ratio is currently 33.84%.

Analysts Set New Price Targets

NVS has been the subject of a number of research analyst reports. BMO Capital Markets initiated coverage on Novartis in a research report on Friday, February 23rd. They issued a “market perform” rating and a $114.00 target price for the company. Morgan Stanley started coverage on Novartis in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $114.00.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.